Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MPLT vs FDMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MPLT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)

MPLT Overall Winner 6-Pillar Tally: MPLT 3 – 2 FDMT (1 Tie) Matrix Metrics: MPLT 4 – 4 FDMT

As of Nov 16, 2026, MapLight Therapeutics, Inc. (MPLT) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MPLT carries a Unified Composite Score of 50.4/100 (HOLD) at $6.94 (N/M Forward P/E, 0.0% operating margin), whereas FDMT carries 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin).

  • Growth vs. Quality Trade-Off: MPLT earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. FDMT 42.1/100 HOLD) and 1.05β · 78% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: MPLT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7); meanwhile FDMT is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MPLT vs FDMT
MPLT US Equity Head-to-Head Winner
MapLight Therapeutics, Inc.
Pharmaceutical Preparations
$6.94
-4.28% 1D
Market Cap $392.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 78% Vol
Unified Composite Score
50.4 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 64.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.2%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $7.44 · SMA50: $9.21
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.65
-4.74% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.89β · 90% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 21.0 Fund 54.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $12.12 · SMA50: $13.08

6-Pillar Scorecard Institutional Category Breakdown (MPLT 3 – 2 FDMT)

Columns: Metric · MPLT · FDMT
1. Valuation Multiples FDMT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 6.6x
2. Growth & Scale FDMT
Revenue Growth (YoY) +0.0% +4505.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $96M
Market Cap $392.9M $669.3M
3. Profitability & Quality MPLT
Gross Margin N/A N/A
Operating Margin 0.0% -222.7%
Net Profit Margin 0.0% -208.6%
Return on Equity (ROE) -111.5% -56.7%
4. Balance Sheet & Cash Flow MPLT
Cash Generation (TTM) -$175M -$156M
Cash Flow Margin N/A N/A
Net Cash / Leverage $70M Net Cash $31M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MPLT
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 92.5% (8th %ile) 82.4% (10th %ile)
Put/Call OI Skew 0.02x (Call-Skewed) 5.16x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MPLT (4) vs FDMT (4)
Institutional Metric MPLT FDMT Criterion Row Edge
Market Capitalization
Scale
$392.9M $669.3M Larger Scale FDMT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +4505.6% Higher Growth FDMT
Operating Margin (TTM)
Profitability
0.0% -222.7% Higher Margin MPLT
Net Profit Margin
Profitability
0.0% -208.6% Higher Margin MPLT
Return on Equity (ROE)
Capital Efficiency
-111.5% -56.7% Higher ROE FDMT
52-Week Range Position
Momentum
3% ($6–$40) 47% ($7–$17) Stronger Trend FDMT
Beta / 30D Volatility
Risk Regime
1.05β · 78% Vol 1.89β · 90% Vol Lower Realized Risk MPLT
Unified Institutional Score
Composite Signal
50.4 / 100 (HOLD) 42.1 / 100 (HOLD) Higher Composite MPLT
Trailing 12M Revenue (USD)
Operating Scale
N/A $96M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$175M ($70M Net Cash) -$156M ($31M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FDMT +5.83 pp
MPLT: -9.87% · FDMT: -4.04%
3M Horizon FDMT +20.43 pp
MPLT: -41.29% · FDMT: -20.86%
6M Horizon FDMT +113.08 pp
MPLT: -73.81% · FDMT: +39.27%
1Y Horizon FDMT +64.73 pp
MPLT: -51.4% · FDMT: +13.33%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MPLT vs FDMT. Trailing 12-month operating profitability (MPLT 0.0% vs FDMT -222.7%) and valuation multiples (MPLT N/M vs FDMT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MPLT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-111.5% · N/M
FDMT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$96M
Gross MarginN/A
Op. Margin-222.7%
ROE / Fwd P/E-56.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MPLT BREAKDOWN
144d in phase · OBV ACCUMULATION
Current IV 92.5%
IV Percentile 8th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact MPLT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MPLT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $392.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MPLT vs FDMT Key Questions & Quantitative Answers

As of Nov 16, 2026, MapLight Therapeutics, Inc. (MPLT) is the stronger overall head-to-head candidate over 4D Molecular Therapeutics, Inc. (FDMT) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MPLT carries a Unified Composite Score of 50.4/100 (HOLD) at $6.94 (N/M Forward P/E, 0.0% operating margin), whereas FDMT carries 42.1/100 (HOLD) at $11.65 (N/M Forward P/E, -222.7% operating margin). Growth vs. Quality Trade-Off: MPLT earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. FDMT 42.1/100 HOLD) and 1.05β · 78% Vol risk profile, whereas FDMT leads top-line expansion (+4505.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MPLT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.7); meanwhile FDMT is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: MPLT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FDMT at +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin). On trailing 12-month operating scale, MPLT generates N/A in USD-normalized revenue versus $96M for FDMT. In operating R&D and SG&A reinvestment, MPLT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FDMT.

FDMT screens cheaper on headline valuation multiples. MPLT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MPLT (-111.5% ROE) versus FDMT (-56.7% ROE) capital efficiency.

In options market volatility and institutional positioning, MPLT carries 92.5% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.05β · 78% Vol realized risk). By comparison, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.